Acceptability and potential impact on uptake of using different risk stratification approaches to determine eligibility for screening: A population-based survey.


Journal

Health expectations : an international journal of public participation in health care and health policy
ISSN: 1369-7625
Titre abrégé: Health Expect
Pays: England
ID NLM: 9815926

Informations de publication

Date de publication:
04 2021
Historique:
revised: 15 10 2020
received: 05 06 2020
accepted: 15 11 2020
pubmed: 3 12 2020
medline: 2 10 2021
entrez: 2 12 2020
Statut: ppublish

Résumé

Using risk stratification approaches to determine eligibility has the potential to improve efficiency of screening. To compare the public acceptability and potential impact on uptake of using different approaches to determine eligibility for screening. An online population-based survey of 668 adults in the UK aged 45-79 including a series of scenarios in the context of a potential kidney cancer screening programme in which eligibility was determined by age, sex, age and sex combined, a simple risk score (age, sex, body mass index, smoking status), a complex risk score additionally incorporating family history and lifestyle, or a genetic risk score. We used multi-level ordinal logistic regression to compare acceptability and potential uptake within individuals and multivariable ordinal logistic regression differences between individuals. Using sex, age and sex, or the simple risk score were less acceptable than age (P < .0001). All approaches were less acceptable to women than men. Over 70% were comfortable waiting until they were older if the complex risk score or genetics indicated a low risk. If told they were high risk, 85% would be more likely to take up screening. Being told they were low risk had no overall influence on uptake. Varying the starting age of screening based on estimated risk from models incorporating phenotypic or genetic risk factors would be acceptable to most individuals and may increase uptake. Two members of the public contributed to the development of the survey and have commented on this paper.

Sections du résumé

BACKGROUND
Using risk stratification approaches to determine eligibility has the potential to improve efficiency of screening.
OBJECTIVES
To compare the public acceptability and potential impact on uptake of using different approaches to determine eligibility for screening.
DESIGN
An online population-based survey of 668 adults in the UK aged 45-79 including a series of scenarios in the context of a potential kidney cancer screening programme in which eligibility was determined by age, sex, age and sex combined, a simple risk score (age, sex, body mass index, smoking status), a complex risk score additionally incorporating family history and lifestyle, or a genetic risk score.
OUTCOME MEASURES
We used multi-level ordinal logistic regression to compare acceptability and potential uptake within individuals and multivariable ordinal logistic regression differences between individuals.
RESULTS
Using sex, age and sex, or the simple risk score were less acceptable than age (P < .0001). All approaches were less acceptable to women than men. Over 70% were comfortable waiting until they were older if the complex risk score or genetics indicated a low risk. If told they were high risk, 85% would be more likely to take up screening. Being told they were low risk had no overall influence on uptake.
CONCLUSIONS
Varying the starting age of screening based on estimated risk from models incorporating phenotypic or genetic risk factors would be acceptable to most individuals and may increase uptake.
PATIENT OR PUBLIC CONTRIBUTION
Two members of the public contributed to the development of the survey and have commented on this paper.

Identifiants

pubmed: 33264472
doi: 10.1111/hex.13175
pmc: PMC8077132
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

341-351

Subventions

Organisme : Medical Research Council
ID : MC_UU_12015/4
Pays : United Kingdom
Organisme : Department of Health
ID : RM-SR-2017-09-009
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00006/6
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C55650/A21464
Pays : United Kingdom

Informations de copyright

© 2020 The Authors. Health Expectations published by John Wiley & Sons Ltd.

Références

BMC Public Health. 2016 Mar 02;16:213
pubmed: 26935960
Ann Behav Med. 2017 Oct;51(5):718-729
pubmed: 28290066
JAMA Oncol. 2018 Nov 1;4(11):1504-1510
pubmed: 29978189
Public Health Genomics. 2013;16(3):94-9
pubmed: 23363703
Sci Rep. 2017 Nov 16;7(1):15698
pubmed: 29146923
BMJ Open. 2018 Jan 23;8(1):e017717
pubmed: 29362249
Acta Oncol. 2016;55(1):45-51
pubmed: 25990635
J Med Screen. 2020 Mar;27(1):52-56
pubmed: 31575328
Ann Intern Med. 2011 Jul 5;155(1):10-20
pubmed: 21727289
Eur Urol. 2019 Jun;75(6):891-893
pubmed: 30910343
Genet Med. 2013 Oct;15(10):810-6
pubmed: 24030434
BMJ. 2016 Mar 15;352:i1102
pubmed: 26979548
Br J Cancer. 2016 Apr 26;114(9):1045-52
pubmed: 27022688
Eur J Hum Genet. 2017 Jun;25(7):832-838
pubmed: 28488675
BMC Womens Health. 2016 Jul 26;16:46
pubmed: 27460568
J Public Health (Oxf). 2017 Mar 1;39(1):113-121
pubmed: 26834190
Breast Cancer Res Treat. 2012 Apr;132(2):365-77
pubmed: 22037780
Front Oncol. 2013 Aug 20;3:207
pubmed: 23971005
BMJ. 2019 Oct 02;367:l5515
pubmed: 31578196
World J Urol. 2018 Sep;36(9):1341-1353
pubmed: 29610964
Health Expect. 2021 Apr;24(2):341-351
pubmed: 33264472
Br J Cancer. 2015 Feb 3;112(3):562-6
pubmed: 25535731
CMAJ. 2018 Apr 9;190(14):E422-E429
pubmed: 29632037
JAMA Oncol. 2018 Nov 1;4(11):1484-1485
pubmed: 29978191
Nat Genet. 2013 Apr;45(4):349-51
pubmed: 23535723
JAMA Netw Open. 2018 Dec 7;1(8):e185461
pubmed: 30646275
Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1580-1593
pubmed: 31292139
Health Expect. 2018 Dec;21(6):1150-1158
pubmed: 30085384
Clin Lung Cancer. 2016 Mar;17(2):95-106
pubmed: 26712102
Public Health Genomics. 2011;14(4-5):238-47
pubmed: 20090298
Breast. 2015 Jun;24(3):237-41
pubmed: 25708717
Eur Urol Focus. 2021 Mar;7(2):407-419
pubmed: 31530498
Can Urol Assoc J. 2017 Dec;11(12):379-387
pubmed: 29106364

Auteurs

Juliet A Usher-Smith (JA)

The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Laragh L W Harvey-Kelly (LLW)

University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK.

Sabrina H Rossi (SH)

Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.

Hannah Harrison (H)

The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Simon J Griffin (SJ)

The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Grant D Stewart (GD)

Department of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH